

## HEADLINES

### **Sponsored Research and the American Recovery and Reinvestment Act of 2009**

The NIH and NSF have begun to announce several programs for delivering economic stimulus funds out to institutions. We will be emailing relevant opportunities to the research community as they are announced. At this point, infrastructure awards – funds for equipment (both shared and high-end cost), alterations and renovations, and construction – are priorities for funding. The second major (and largest) category of funding is for peer-reviewed science that would benefit from a two-year boost. NIH is specifically considering using administrative supplements to ongoing projects, Challenge Grants for new projects, competitive supplements adding new scope/aims to existing projects, and short-term grants among the 14,000 proposals that were deemed worthy of funding by study sections and advisory councils but had no funds available under the regular appropriation.

Dr. Raynard Kington, Interim Director of the NIH, held a conference call with members of the AAMC and stated that investigators will be approached by program officials for administrative supplements and the short-term grants. For these, NIH will be comparing specific aims and the programmatic interests of the institute as well as the ability of the project to show significant advances in the science in a two-year time period. They will not be “calling down the list” in order of priority score. Program announcements and requests for applications will drive the infrastructure, competitive supplements, and Challenge Grants.

#### **What do you need to know?**

- **Be ready to move quickly** – Both program announcements and direct approaches from NIH will have short turn around times. The research administration structure at UM will be very supportive getting things out the door!
- **Be ready to rethink your costs and discuss them** – We are anticipating that if a four- or five-year program is negotiated down to two years, the scientific scope, and therefore the financial needs of the program may be significantly different. And as you re-budget your project, think in terms of items you need that would yield economic benefit. Cited as an exceptional use of funds was the possibility of a postdoc staying in a lab instead of trying to find a job in a slow job market. A one-time equipment purchase that might help other local economies was also mentioned as compelling.
- **Be ready to spend** – If you do receive stimulus funds, NIH would like them spent as quickly as possible. They are under the requirement of awarding them by September 2010, and overseeing their expenditure. In the phone conference, Dr. Kington specifically said

they would also like to see a bulk of the funds spent by 2010. NSF has been less aggressive so far when talking about their spending expectations.

- **Be ready to report** – Stimulus funds are different than dollars from a federal agency’s yearly appropriation. These funds will carry special reporting requirements about job creation and expenditure rates. Read your award notices carefully and understand the role you play in getting information back to sponsors.

This is a unique opportunity, and we hope that many will have the chance to participate. If you have questions or would like to talk to someone about options, we advise you to be in touch with your department research administration staff or contact the Office of Research’s Grant Review & Analysis unit (hmills@umich.edu). We will do our best to connect you to needed resources in order to advance your science. Read more about the stimulus funds to NIH below in the “Update from Washington, DC” section.

### **Annual Outside Interest Disclosure Required Using M-Inform**

**Deadline: March 31, 2009**

As in previous years, all Medical School faculty members (instructional, clinical and research tracks) are required to disclose their outside interests annually each March 1 and as needed, indicating any involvement with University related activities outside the scope of their primary responsibility as a University faculty member. New this year is the inclusion of all house officers in this reporting requirement.

To comply with this UMHS Conflict of Interest policy, certain executives and management staff must also disclose their outside interests for themselves and their family members.

Key Points Include:

1. Outside Interest Disclosure Form (M-Inform) must be completed between March 1 and March 31.
2. Disclosure forms will be reviewed between April 1 and April 30, with follow-up as needed.
3. Upon signing and submitting the form, MLearning will track your completion.
4. Disclosures and any additional information gathered shall be treated as sensitive data, and access to this information is granted only to those University or UMHS personnel requiring such information to perform their duties.
5. The UMHS Conflict of Interest and Outside Interest Disclosures website (<http://www.med.umich.edu/u/coi>) is available to provide additional information on this process.

Access to M-Inform is at (<http://www.umms.med.umich.edu/minform/>). This electronic format provides an easy mechanism for submitting disclosures and allows participants to copy activities disclosed in 2008 into their

2009 record as needed. Additional information can be found at (<http://www.med.umich.edu/u/coi>), and additional support is available by contacting ([coi-oid-questions@med.umich.edu](mailto:coi-oid-questions@med.umich.edu)).

### **BAC Recombineering Core Update**

Bacterial artificial chromosome (BAC) libraries with all the genes from human, mouse and other species are commercially available. Modification of the large genomic inserts to reproduce disease-causing mutations or to mark cells expressing certain genes is done by recombineering. The Recombineering Core Facility was established in the Transgenic Core by a partnership with the Endowment for the Basic Science, the Diabetes Research and Training Center, the Cancer Center, the Gastrointestinal Peptide Center, the Life Sciences Institute and the Center for Organogenesis. The Recombineering Core has set up a wet lab for and is recombineering BACs for pilot projects. Several BACs have been successfully modified with lacZ and red fluorescent proteins. Plasmid vectors to introduce other genetic markers (green fluorescent protein and Cre recombinase) are under construction in the Core. DNA sequencing of modifications and BAC fingerprinting are used for quality control purposes. We will continuously refine our methodology as we work through pilot projects. After we recombineer a few more BACs we will open the BAC Recombineering Core to the research community at large. If you are interested in BAC services, please contact Thom Saunders ([tsaunder@umich.edu](mailto:tsaunder@umich.edu)).

## **RESEARCH COMPLIANCE TRAINING AND EDUCATION**

### *Human Research*

#### **eResearch Regulatory Management System Upgrade**

The eResearch Regulatory Management system was upgraded on Monday, March 2, 2009. The upgrade or enhanced system release 2.0 is in response to feedback received from investigators and study teams requesting a more streamlined application. The enhancements for this upgrade include:

- New look and feel for the system workspaces and forms.
- Improved help sections.
- New, shorter, customized application paths for **Exempt** and **Not Regulated** projects.
  - An Exempt research application path that is limited to information necessary to determine whether a project meets the exemption criteria.
  - A Not Regulated application path for projects that do not fall under HHS or FDA regulations. For projects that do not require IRB review, the Not Regulated path can be used to generate a self-determination letter for funding or publication purposes. For projects that require IRB review only for compliance with HIPAA, other regulations or institutional policies, the Not Regulated path is limited to questions relevant to those determinations.
- A **NEW Edit Study Team Member Activity** has been added which will allow study teams to edit “non-key

personnel” to have access to approved studies without having to submit an amendment. Study team members with the role of Staff, Consultant, or Other are considered non-key personnel.

- Updated amendment approval process so that only changes requiring review by ancillary and non-IRB core committees will be routed to those committees.

Because of the streamlining project, many questions that were not required have been deleted from the application. For example, with the new Exempt customized application path, a total of 57 questions have been eliminated from that application process. Approximately five questions have been added due to regulatory changes and certification requirements for the Association for the Accreditation of Human Research Protection Programs (AAHRPP).

For more information and detail about this release, please refer to ([http://www.umich.edu/~eresinfo/erm/release2\\_0.html](http://www.umich.edu/~eresinfo/erm/release2_0.html)). For more information on what types of human subjects research are considered Exempt or Not Regulated, please refer to (<http://www.research.umich.edu/hrpp/OM/Part4.html>). For questions or further assistance, contact the MAIS Help Desk (734-936-7000, option 6 or [maishelpdesk@umich.edu](mailto:maishelpdesk@umich.edu)) or a U-M IRB (<http://www.research.umich.edu/hrpp/IRBs.html>).

### *Animal Research*

#### **Safety Reminder for the Research Facilities**

The University of Michigan maintains an exemplary animal care and use program. Our animal care and use program maintains full compliance with federal and state regulations and policies, as well as nationally accepted professional standards. Because we are indebted to animals for their valuable contributions to our research and instructional endeavors, and because animal well-being is critical to good science, the University ensures that animals are used in a responsible, respectful, and humane manner. However, there are individuals that disagree with the use of animals in research. Because of this, we should all be especially alert to maintaining security in and around our laboratories and animal facilities.

The Department of Public Safety (DPS) always recommends that the research community take the following precautions:

- Keep laboratories and offices locked.
- Monitor laboratories and offices for unauthorized persons.
- Wear identification badges at all times.
- Report suspicious persons, activity, or objects to DPS immediately (call 911).
- Report inquiries regarding building hours, locations of laboratories and offices, type of research being conducted, and location of animals to DPS (734-763-3434).

#### **Inspections of Animal Facilities**

Both the Public Health Service Policy (PHS Policy) and the Animal Welfare Regulations require semi-annual inspections of animal facilities. In March/April and September/October, the UCUCA inspects animal housing and use rooms, facilities, and laboratories using the “Guide for the Care

*Biomedical News • March 2009*

and Use of Laboratory Animals” as a basis for evaluation. In addition, the UCUCA compliance staff inspects laboratory spaces that conduct rodent survival surgeries semi-annually on behalf of the UCUCA. The results of these inspections are reviewed by the UCUCA at a monthly meeting and sent in a report to the Vice President for Research twice each year.

### **Animal Concern Hotline**

The UCUCA maintains the Animal Concern Hotline, operated through the UCUCA Office, to provide a mechanism for UM staff members and members of the public to report any matter of concern about the humane care and use of laboratory animals at the University. Reports are investigated on behalf of the UCUCA by the UCUCA Office staff and, if necessary, by a ULAM veterinary faculty member. Immediate steps are taken to ensure that animal care and use are appropriate and that animal welfare is sustained. The UCUCA is apprised of these investigations and their outcomes at their monthly meetings and makes further recommendations, if warranted. Reports and sources of information are maintained in confidence within University guidelines. To report an animal concern, please call 734-763-8028 or go to (<http://www.ucuca.umich.edu/hotline.htm>).

### **Training**

Animal care training is based on regulatory requirements (Public Health Service Policy and the Animal Welfare Act) and the commitment of the University of Michigan to ensure that animal research performed here is done in the most humane and effective manner. As the animal research program has grown over the years, it had become necessary to increase staff and develop new ways of providing support to animal users. In order to improve the utilization of training resources, increase the coordination of training activities and messages, and reduce redundancy in training, all of the training provided by ULAM and UCUCA is now combined into a centralized unit called the **ULAM Training Core**. By having trainers from each area work together we have improved the consistency and availability of courses offered to all of our customers.

The training core offices and wet laboratory moved from the North Ingalls Building (NIB) to the Life Sciences Building (LSI). Training is coordinated through the Training Core instead of the UCUCA office.

#### **Training Core Offices**

Location: 1016 LSI

Phone: 734-763-8039

Email: [ulamtraining@umich.edu](mailto:ulamtraining@umich.edu)

Website: <http://www.ulam.umich.edu/training.htm>

## **FREQUENTLY ASKED QUESTIONS**

The frequently asked questions (FAQs) highlighted here come from a list of FAQs for research maintained by the Office of Research. To see the complete list, visit (<http://www.med.umich.edu/medschool/research/faq.htm>).

### **Q) What do I do if I am offered (and accept) a significant financial interest outside of the University? How do I report a potential conflict of interest?**

**A)** First, faculty and management staff will need to disclose their outside activity or interest in M-Inform (<https://www.umms.med.umich.edu/minform/>). M-Inform is the electronic disclosure system that will route your disclosure to your department chair or supervisor for approval. For visiting faculty, adjunct faculty, and all other staff, their potential conflicts of interest should be disclosed to their supervisor. For the disclosure form, visit ([http://www.med.umich.edu/u/coi/Files/Blank\\_Disclosure\\_Form\\_-\\_M-Inform.pdf](http://www.med.umich.edu/u/coi/Files/Blank_Disclosure_Form_-_M-Inform.pdf)).

In addition, potential conflicts of interest need to be disclosed on Page 2 of the Proposal Approval Form or Material Transfer Form used by DRDA. eResearch also includes conflict of interest questions that will route potential conflicts to the appropriate committee for review.

Finally, if you are involved in a UMHS committee, you should advise your committee chair of any potential conflict related to your role on the committee.

## **FROM THE GRANTS OFFICE**

### **Grants.gov and Adobe Forms**

Many of you are aware that Grants.gov has moved electronic form submission from PureEdge to an Adobe platform. MSIS- and MCIT-supported computers in the Health System have had appropriate versions loaded. While many are glad to have moved away from PureEdge forms and the problems associated with them, Adobe-based form sets are not free of glitches.

While improvements are being made, please read below highlights from Bob Beattie’s and Terri Maxwell’s (both of DRDA) warnings of glitches in the form sets and delivery system. We are sure that having investigators cognizant of the issues will help expedite problem solving.

- **Be ready to submit early.** Not just early in any deadline cycle, but early in the morning! Having a proposal finalized and loaded for DRDA to send in the morning hours will offer a better success of getting through Grants.gov and the NIH Commons. DRDA is experiencing noticeably slower (and impaired) submission delivery as the West Coast “wakes up” and is also submitting. Grants.gov has released a new server that has higher capacity, but there continues to be noticeable slow downs through the early-March deadlines.
- **Uploading your application to the DRDA “drop box” does not count as meeting a sponsor deadline.** Moreover, our trying to submit an application to Grants.gov does not meet the deadline either. Only a successful submission to Grants.gov will meet deadline requirements.

- **Upload only the final version to the DRDA server.** (This requirement will be obsolete as we start to use eRPM in April and can specify versions that are ready to go through the system.) You do not want to cause confusion between draft versions and finals to be sent. If you need someone to look at draft, attach it to an email!
- **Be sure you are using the correct version of Adobe.** As mentioned above, MSIS and MCIT have distributed (to imaged computers) versions of Adobe that are compatible. If you are using non-UM resources to prepare a proposal or a non-imaged campus computer, please make sure you are carrying 8.1.2, 8.1.3 or 9.0 version of Adobe Reader. There have been occasional issues reported with 8.1.2 and crashes that cause loss of data. Please make sure in 8.1.2 you are saving often – just in case.

Also, Bob Beattie has provided detailed information around the use of Key Personnel on Grants.gov forms:

A serious error has been discovered in the Adobe Forms concerning the Key Personnel section. If there is only one Key Person, other than the PI, once a “Role in Project” is selected the data cannot be removed. This means that the person cannot be removed and the application cannot be submitted due to missing data in the other fields. If you expect to have only one Key Person in an application, I suggest you do not select the role on project for that person until just before you send the forms to the DRDA Dropbox. You might otherwise consider having two versions of the application, a completed one, and one lacking this field. Use the full application for creating materials for the Administrative Shell, and if the one Key Person stays with the project, upload that version. If, however, that one Key Person drops out of the project, use the incomplete version and remove the other data for that person and upload this version. If you find yourself with one Key Person, feel free to call me for further information, if you need it.

The Medical School is very appreciative of the information passed along from campus as well as for the dedication of the DRDA staff dealing with Grants.gov and Adobe forms under fire of deadlines!

If you have questions about this article, please contact Heather Offhaus in the Medical School Grant Review & Analysis Office (734-763-4272).

## UPDATE FROM WASHINGTON, DC

### NIH Receives \$10.4 Billion in Economic Stimulus Funds

On February 17, 2009, President Barack Obama signed the American Recovery and Reinvestment Act (ARRA) into law. Of the \$789 billion total, \$10.4 billion will be allocated to the National Institutes of Health (NIH) to support research, construction and renovation activities. Below is a summary of how the NIH plans to spend the ARRA money. It is important to note that all information related to ARRA implementation can be found at a new federal website named “recovery.gov.”

## Research

- \$8.2 billion for biomedical research.
  - \$7.4 billion for the Institutes and Centers and the Common Fund. These funds will be allocated in proportion to the FY09 appropriations made to the Institutes, Centers, and Common Fund.
  - \$800 million for the Office of the Director for short-term grants. These grants will focus on specific challenges, new research that expands the scope of ongoing projects and research on public and international health priorities.
- Research funding will be allocated in one of three ways:
  - Standard investigator grants judged to be “highly scientifically meritorious” in peer review last year but did not receive funding.
  - Supplements to existing grants (such additions will not be made by formula but will be based on scientific opportunity and public health needs).
  - Two-year Challenge Grants aimed at supporting cross-cutting research.
- All grants to be made assuming a two-year obligation and expense.
- The selections will be made on the basis of peer review, with emphasis on the short-term stimulative nature of the proposal.
- There will be no automatic funding of existing proposals or grants.
- Reporting requirements will be more extensive (e.g. number of jobs retained or created will be required).
- There will be no formulaic restoration of money to centers or grants that during negotiations received less than requested.
- Unlike the earlier House and Senate bills, the final bill does not highlight specific areas of research as priorities.

## Infrastructure

- \$1.3 billion for construction and renovation as well as shared instrumentation.
  - \$1 billion for competitive awards for construction and renovation of extramural research facilities. Priority will be given to proposals that demonstrate energy savings or beneficial environmental effects.
  - \$300 million for shared instrumentation.

## EDUCATIONAL OPPORTUNITIES

### 44th Graduate Summer Session in Epidemiology

#### Application Deadline: June 1, 2009

(Applications received by the deadline does not guarantee placement in a course. Enrollment is limited in a number of courses.)

The University of Michigan School of Public Health will offer one-week and three-week courses for all public health professionals and those interested in health research during their 44th Graduate Summer Session in Epidemiology to take place July 12-31, 2009. Topics include: Fundamentals of Biostatistics and Epidemiology, Intermediate Methods, Infectious Diseases, Applied Public Health Practice, Cancer Epidemiology, Clinical Trials, SAS, Logistic Model,

Linear Regression, Survival Analysis, Behavioral Change, Social Epidemiology, Longitudinal Studies, Global Health, Pharmacoepidemiology, Surveillance, Multi-level Analysis in Public Health, Scientific Writing, Geographic Information Systems, Health Policy, Environmental and Occupational Epidemiology, Community-Based Research, Evolutionary Epidemiology.

- Distance Learning Courses:
  - Fundamentals in Biostatistics
  - Fundamentals of Epidemiology
- CME credit available

For application and information, visit (<http://www.sph.umich.edu/epid/GSS>). For questions, contact Jody Gray at 734-764-5454 or ([umichgss@umich.edu](mailto:umichgss@umich.edu)).

## FUNDING/AWARD OPPORTUNITIES

Funding opportunities listed below are for external limited submissions and/or opportunities within the University of Michigan only. To search for other funding and recognition opportunities, visit (<http://www.med.umich.edu/medschool/research/support/funding.htm>). This webpage contains a link to M-Quest (a database of opportunities for grants, honors, prizes and fellowships created and maintained by the Office of Research) as well as information on email alert groups.

### *Internal Submissions*

#### **Michigan Institute for Clinical and Health Research (MICHHR) CTSA K Scholars Program** **Deadline: Extended to March 16, 2009**

The Michigan Institute for Clinical and Health Research is pleased to announce an extension in the application period and a revision to the funding support mechanism for the CTSA K Scholars-Mentored Clinical Scientists Development Program. The revision provides for full funding of two awarded scholars and partial-funding of four additional scholars. The top two applicants will be awarded full financial and training support for salary, research expenses and tuition fees. Four additional scholars will receive a total of \$55,000 of support per year for research expenses and tuition/workshop fees. Partially funded scholars will be responsible for obtaining salary support from their clinical departments. The CTSA K Program is a two-year program offered to candidates from all healthcare-related schools and clinical departments who seek training as a clinical/translational research scientist. All applicants must obtain 75 percent protected time (50 percent for surgical sub-specialties) from their clinical departments. Applications can be obtained by visiting (<http://www.michr.umich.edu/KL2/>).

#### **Michigan George M. O'Brien Renal Core Center Pilot/Feasibility Study Grant Program** **Deadline: March 17, 2009 (Letter of Intent)**

New and innovative approaches—clinical, translational and basic—are sought to study kidney disease. The Michigan George M. O'Brien Renal Core Center P/FS Grant Program provides funds to promote research initiatives by new and

established University of Michigan faculty in the area of kidney disease. Particularly encouraged are applications from junior investigators and investigators external to the renal community who have training and expertise that can be applied in innovative fashion to the study of kidney disease. The goal of the program is to enable investigators to generate preliminary data sufficient to successfully apply for major research funding from national funding agencies.

The grants are up to \$50,000 per year for up to two years. Eligible investigators include: (1) new investigators without current or past NIH support as a principal investigator, and whose current or previous support from other sources has been modest; (2) established investigators with limited previous kidney research experience who wish to apply their expertise to a problem in this area; and (3) established renal investigators who propose testing innovative ideas that represent a clear departure from their ongoing research directions. Visit (<http://www.med.umich.edu/medschool/research/support/kidneyresearch.pdf>) for more information.

#### **Rheumatic Diseases Core Center Pilot and Feasibility Research Funding** **Deadline: April 10, 2009**

Faculty members of the University of Michigan are invited to submit proposals for pilot and feasibility research projects to be funded through the U-M Rheumatic Diseases Core Center (RDCC) grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The Rheumatic Diseases Core Center is a multidisciplinary National Institutes of Health funded center that supports research in the etiology and pathogenesis of rheumatic diseases.

Eligible investigators include:

- New investigators without current or past NIH research project support (R01, P01, or current R55) as a principal investigator to engage in innovative research. New investigators should be clearly independent and have a faculty appointment higher than that of Lecturer/Postdoctoral fellow.
- Established investigators with no previous work in research related to the focus of the RDCC who are willing to test the applicability of their expertise on a problem related to rheumatic diseases.
- Established investigators in the RDCC with a proposal for testing the feasibility of a new or innovative hypothesis that is related to the research focus of the RDCC, but represents a clear and distinct departure from the investigator's ongoing research interest.

For more information, visit ([http://sitemaker.umich.edu/rheumaticdiseasescorecenter/call\\_for\\_applications](http://sitemaker.umich.edu/rheumaticdiseasescorecenter/call_for_applications)).

#### **MICHHR / CTSA Pilot and Collaborative Grant Program in Clinical and Translational Research** **Deadline: Extended to April 15, 2009**

As part of the NIH Roadmap Clinical and Translational Sciences Award (CTSA), the Medical School, Faculty Group Practice, Health System, and many University departments, schools, centers, and institutes, have partnered with MICHHR to announce Round Six of the Pilot Grant Program. The goal

of this RFA is to facilitate and support clinical translational research in its many forms and to encourage interdisciplinary collaboration.

Proposals are sought from basic, clinical and social scientists from bench to bedside, bedside to practice, practice to interventions, and dissemination to policy research to promote development of transformative solutions for improving patient outcomes. All faculty and post-doctoral trainees at UM are eligible to apply as Principal Investigators. Basic scientists are encouraged to submit their application with a clinical scientist collaborator.

Special Focus RFAs supporting the CTSA vision requested for this round include "Community-University Research Partnerships," "Health Disparities Research" and "Research Ethics." New this round, the "Research Into Practice" focus RFA seeks investigators to develop and lead clinical translational research studies in partnership with GRIN, the Great Lakes Research Into Practice Network. The MICHR Research Into Practice program supports one-year pilot and/or feasibility research studies of innovative interventions and/or techniques designed to improve/benefit the health of the community.

For more details regarding Pilot Grant Program, descriptions of grant mechanisms and application instructions, visit (<http://www.michr.umich.edu/programs/pilot-grant.html>). For questions, contact Carol Van Huysen, MICHR Pilot Program Manager (734-998-6885 or [cvanh@umich.edu](mailto:cvanh@umich.edu)).

### **Michigan Gastrointestinal Peptide Research Center Pilot Feasibility Projects**

#### **Deadline: April 17, 2009**

The Michigan Gastrointestinal Peptide Research Center invites applications for Pilot Feasibility Projects in any of the following areas:

- Regulatory peptide biology
- Gastrointestinal Peptidergic Function
- Other areas of gastrointestinal function or pathology
- Microarray Gene Chip Technology and Proteomics applications designed to elucidate peptide involvement in GI function and pathology.

First priority will be given to young investigators at the University of Michigan embarking on a research career, with the hope that the Pilot Feasibility Project will lead to the successful funding of an RO1 type application. **At least three years of postdoctoral training is required prior to the start of the award. Postdocs meeting this requirement, instructors/lecturers and young faculty through Assistant Professors are welcome. More senior investigators will be considered only if the project represents a new direction in their research, and will be given lower priority.**

Grants will be awarded for \$10,000 to \$25,000; the maximum request is for \$25,000/year. A maximum of two years of funding will be provided. For complete information, visit (<http://www.med.umich.edu/mgpc/pilot>).

### **UM Postdoctoral Translational Scholars Program**

#### **Deadline: April 17, 2009**

The Postdoctoral Translational Scholars Program is a multidisciplinary career development program supported by the Michigan Institute for Clinical and Health Research (MICHR) that is designed to prepare individuals with a Ph.D. in a biomedical science or social science discipline for independent careers in translational research. **The program is open to talented individuals who have completed a Ph.D. program in any of the basic sciences or related areas (biomedical, health, or social sciences) and aspire to develop a career in clinical translational research. Candidates must be a U.S citizen or permanent resident.**

The program will provide trainees with a \$100,000 career development award that can be utilized over two to three years. Award funding can be used to support the individual's stipend, course work, and/or research activities. Postdoctoral Translational Scholars will be expected to commit 50 to 75 percent of full time effort to the program. For more information and an application, visit (<http://www.michr.umich.edu/ptsp>).

• • • *Deadline Watch* • • •

### **UM Henry Russel Lectureship**

([http://www.rackham.umich.edu/faculty\\_staff/](http://www.rackham.umich.edu/faculty_staff/))

## **UMMS AWARDED GRANTS**

### *External Awarded Grants*

Currently, due to limitations on data collection, we are unable to identify projects awarded with multiple PIs. As the eRPM system is used for proposals in 2009, we will be able to publish those awards accurately. We apologize for any misleading project information this causes.

#### **Cell & Developmental Biology**

---

**PI:** Giger, Roman  
**Title:** DEVELOPMENT OF MONOCLONAL ANTIBODIES SPECIFIC FOR DEGENERATING CNS MYELIN  
**Sponsor:** Adelson Medical Research Foundation  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$24,158

**PI:** Giger, Roman  
**Title:** MECHANISMS OF NEURONAL GROWTH INHIBITION IN VITRO AND IN VIVO  
**Sponsor:** Adelson Medical Research Foundation  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$21,719

#### **Comprehensive Cancer Center**

---

**PI:** Talpaz, Moshe  
**Title:** TAK-901 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (UMCC 2008.046 A PHASE 1 DOSE ESCALATION STUDY OF)  
**Sponsor:** Millenium Pharm, Inc.  
**Project Dates and Amount of Award:** 11/14/08-05/13/10; \$693,914

#### **Dermatology**

---

**PI:** Dlugosz, Andrzej  
**Title:** THE HEDGEHOG PATHWAY IN CANCER DEVELOPMENT AND MAINTENANCE  
**Sponsor:** Helen L. Kay Charitable Foundation  
**Project Dates and Amount of Award:** 01/01/09-12/31/10; \$57,816

## Family Medicine

---

**PI:** Richardson, Caroline  
**Title:** VETERANS WALK TO BEAT BACK PAIN  
**Sponsor:** Veterans Affairs, Dept. of  
**Project Dates and Amount of Award:** 01/01/09-09/30/11; \$120,000

## Internal Medicine

---

**PI:** Buckanovich, Ronald  
**Title:** OVARIAN TUMOR VASCULAR PROTEINS AS BIOMARKERS AND THERAPEUTIC TARGETS  
**Sponsor:** Ovarian Cancer Research Fund, Inc., The (OCRF)  
**Project Dates and Amount of Award:** 01/01/09-12/31/10; \$200,000

**PI:** Chugh, Rashmi  
**Title:** SARC ALLIANCE FOR RESEARCH THROUGH COLLABORATION MEDICAL ADVISOR  
**Sponsor:** SARC  
**Project Dates and Amount of Award:** 12/01/08-03/31/09; \$19,250

**PI:** Chun, Tae-Hwa  
**Title:** 3-DIMENSIONAL PROTEOLYTIC REGULATION OF ADIPOSE TISSUE DEVELOPMENT AND FUNCTION  
**Sponsor:** NIH 1 K08 DK 078801 01 A1  
**Project Dates and Amount of Award:** 07/01/09-06/30/12; \$398,358

**PI:** Fagerlin, Angela  
**Title:** A STUDY TO EVALUATE DIFFERENT DECISION-MAKING APPROACHES USED BY WOMEN KNOWN TO BE AT HIGH RISK FOR BREAST CANCER  
**Sponsor:** NIH - Subcontracts TO NSABP Foundation  
**Project Dates and Amount of Award:** 09/01/08-05/31/09; \$41,426

**PI:** Froehlich, James  
**Title:** FIBROMUSCULAR DYSPLASIA PATIENT REGISTRY  
**Sponsor:** Fibromuscular Dysplasia Society of America  
**Project Dates and Amount of Award:** 01/31/09-02/01/10; \$50,143

**PI:** Hayes, Daniel  
**Title:** INVESTIGATIONS INTO THE BIOLOGY OF CIRCULATING TUMOR CELLS IN METASTATIC BREAST CANCER PATIENTS  
**Sponsor:** Veridex  
**Project Dates and Amount of Award:** 12/23/08-12/22/10; \$100,000

**PI:** Marrero, Jorge  
**Title:** ORAL TAC-101 AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO RECEIVED SORAFENIB AS FIRST LINE THERAPY (A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, INTERNATIONAL, MULTI-CENTER STUDY OF)  
**Sponsor:** Taiho Pharma USA, Inc. TO Quintiles, Inc.  
**Project Dates and Amount of Award:** 02/03/09-12/31/10; \$180,060

**PI:** Martinez, Fernando  
**Co-I:** Coffey, Michael (Int Med-Pulm./Critical Care) / Curtis, Jeffrey (Int Med-Pulm./Critical Care) / Han, Meilan (Int Med-Pulm./Critical Care)  
**Title:** SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURE IN COPD STUDY SPIROMICS; CLINICAL CENTERS  
**Sponsor:** NIH N01 HR 096202  
**Project Dates and Amount of Award:** 02/01/09-01/31/16; \$1,961,990

**PI:** Meddings, Jennifer  
**Co-I:** Rogers, Mary (Int Med-General Medicine)  
**Title:** THE IMPACT OF THE CMS HOSPITAL-ACQUIRED CONDITIONS INITIATIVE FOR MICHIGAN PATIENTS AND HOSPITALS  
**Sponsor:** Blue Cross Blue Shield of Michigan Foundation  
**Project Dates and Amount of Award:** 04/06/09-04/05/11; \$208,728

**PI:** Oral, Elif  
**Title:** PROVIDE METRELEPTIN FOR THE TREATMENT OF DIABETES MELLITUS AND/OR HYPERTRIGLYCERIDEMIA ASSOCIATED WITH LIPODYSTROPHY (AN OPEN-LABEL TREATMENT PROTOCOL TO)  
**Sponsor:** Amylin Pharmaceuticals, Inc.  
**Project Dates and Amount of Award:** 01/22/09-01/21/14; \$102,300

**PI:** Saad, Richard  
**Title:** RIFAXIMIN 550 MG TID IN THE TREATMENT OF SUBJECTS WITH NON-CONSTIPATION IRRITABLE BOWEL SYNDROME (A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF)  
**Sponsor:** Salix Pharmaceuticals, Inc  
**Project Dates and Amount of Award:** 01/29/09-12/31/10; \$81,300

**PI:** Saint, Sanjay  
**Title:** TRANSLATING HEALTHCARE-ASSOCIATED RESEARCH INTO PRACTICE SURVEY  
**Sponsor:** Blue Cross Blue Shield of Michigan Foundation  
**Project Dates and Amount of Award:** 02/01/09-01/31/10; \$75,000

**PI:** Vijan, Sandeep  
**Title:** COMPLEX PATIENT CARE ANALYSIS  
**Sponsor:** Health and Human Services, Department of-Agency for Health Care Research and Quality-Subcontracts TO University of North Carolina  
**Project Dates and Amount of Award:** 09/30/08-09/29/09; \$40,010

**PI:** Wang, Shaomeng  
**Title:** DESIGN OF BIVALENT SMAC MIMETICS  
**Sponsor:** NIH 1 R01 CA 127551 01 A2  
**Project Dates and Amount of Award:** 01/01/09-11/30/13; \$1,534,100

**PI:** Zalupski, Mark  
**Title:** GDC-0449 (SYSTEMIC HEDGEHOG ANTAGONIST) WITH CONCURRENT CHEMOTHERAPY AND BEVACIZUMAB AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (2008.035: A RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY OF)  
**Sponsor:** Genentech, Inc.  
**Project Dates and Amount of Award:** 02/15/09-12/14/10; \$729,582

**PI:** Zhou, Shi-Yi  
**Title:** PLASTICITY OF INTERSTITIAL CELLS OF CAJAL IN DIABETIC GASTROPATHY  
**Sponsor:** American Diabetes Assoc, Inc.  
**Project Dates and Amount of Award:** 01/01/09-12/31/10; \$90,000

## Molecular & Behavioral Neuroscience Institute

---

**PI:** Umemori, Hisashi  
**Title:** SYNAPSE FORMATION BY FIBROBLAST GROWTH FACTORS IN THE BRAIN  
**Sponsor:** March of Dimes Birth Defect Foundation  
**Project Dates and Amount of Award:** 02/01/09-01/31/11; \$150,000

## Molecular & Integrative Physiology

---

**PI:** Rui, Liangyou  
**Title:** REGULATION OF ENERGY AND GLUCOSE METABOLISM BY SH2B1 IN AGRP NEURONS  
**Sponsor:** American Diabetes Assoc, Inc.  
**Project Dates and Amount of Award:** 01/01/09-12/31/09; \$103,500

**PI:** Williams, John  
**Co-I:** Ernst, Stephen (Cell and Developmental Biology)  
**Title:** DIETARY REGULATION OF PANCREATIC DIGESTIVE ENZYMES  
**Sponsor:** NIH 2 R01 DK 059578 06 A2  
**Project Dates and Amount of Award:** 01/20/08-11/30/13; \$1,649,369

## Neurology

---

**PI:** Rainier, Shirley  
**Co-I:** Fink, John (Neurology Department)  
**Title:** CEREBELLAR ATAXIA: THREE NOVEL GENETIC FORMS  
**Sponsor:** National Ataxia Foundation  
**Project Dates and Amount of Award:** 01/01/09-12/31/09; \$15,000

**PI:** Segal, Benjamin  
**Co-I:** Kim, Sinae (Biostatistics Department)  
**Title:** ACE: THE IL-12P40 FAMILY OF MONOKINES IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS  
**Sponsor:** NIH - Subcontracts TO University of Rochester U19 AI 056390  
**Project Dates and Amount of Award:** 07/01/07-03/31/09; \$65,885

**PI:** Vincent, Andrea  
**Title:** NEW THERAPEUTIC TARGETS IN DIABETIC NEUROPATHY  
**Sponsor:** American Diabetes Assoc, Inc.  
**Project Dates and Amount of Award:** 01/01/09-12/31/09; \$92,281

## Neurosurgery

---

**PI:** Thompson Jr, B  
**Co-I:** Zahuranec, Darin (Neurology Department)  
**Title:** CARTOID OCCULSION SURGERY STUDY (COSS)  
**Sponsor:** NIH - Subcontracts TO University of North Carolina  
**Project Dates and Amount of Award:** 12/01/07-11/30/12; \$434,635

## Obstetrics & Gynecology

---

**PI:** As-Sanie, Sawsan  
**Title:** CHARACTERIZATION OF PAIN PROCESSING IN ENDOMETRIOSIS-ASSOCIATED CHRONIC PELVIC PAIN  
**Sponsor:** Bayer Corporation  
**Project Dates and Amount of Award:** 01/01/09-12/31/10; \$110,000

## Ophthalmology & Visual Sciences

---

**PI:** Thompson, Debra  
**Title:** VISUAL CYCLE DEFECTS IN INHERITED RETINAL DEGENERATION (RPB SENIOR SCL INVEST AWARD)  
**Sponsor:** Research To Prevent Blindness  
**Project Dates and Amount of Award:** 01/01/09-12/31/09; \$75,000

## Otolaryngology

**PI:** Gong, Tzy-Wen  
**Co-I:** Dolan, David (Kresge Hearing Research Inst) / Lomax, Margaret (Kresge Hearing Research Inst)  
**Title:** INTRINSIC THIOREDOXIN AND GLUTATHIONE SYSTEMS: PROTECTION AGAINST NOISE-INDUCED HEARING LOSS  
**Sponsor:** National Organization for Hearing Research, The  
**Project Dates and Amount of Award:** 02/01/09-01/31/10; \$20,000

## Pathology

**PI:** Jo, Stephanie  
**Title:** THE ROLE OF MLL PARTNER ASSOCIATED COMPLEX IN LEUKEMIA  
**Sponsor:** NIH 1 F30 HL 095280 01  
**Project Dates and Amount of Award:** 02/01/09-01/31/12; \$94,674

**PI:** Newton, Duane  
**Title:** DETERMINE PERFORMANCE CHARACTERISTICS OF THE BD GENEHM\*TM CDIFF ASSAY ON FRESH STOOL SPECIMENS COMPARED TO THE CDIFF CHECK "COMMON" ANTIGEN GLUTAMATE DEHYDROGENASE (GDH) EIA, REMEL PROSPECT TOXIN A/B EIA AND CYTOTOXICITY NEUTRALIZATION ASSAYS  
**Sponsor:** Becton, Dickinson and Company  
**Project Dates and Amount of Award:** 02/01/09-07/31/09; \$2,500

## Pediatrics & Communicable Diseases

**PI:** Dowling, James  
**Co-I:** Feldman, Eva (Neurology Department)  
**Title:** THERAPEUTIC RESCUE IN A MODEL OF MULTI MINICORE MYOPATHY  
**Sponsor:** Child Neurology Foundation  
**Project Dates and Amount of Award:** 01/01/09-12/31/10; \$100,000

**PI:** LiPuma, John  
**Title:** BURKHOLDERIA CEPACIA REFERENCE LABORATORY AND REPOSITORY (YEAR 13)  
**Sponsor:** Cystic Fibrosis Foundation  
**Project Dates and Amount of Award:** 03/01/09-02/28/10; \$393,601

**PI:** Nasr, Samya  
**Title:** THERAPEUTICS DEVELOPMENT NETWORK  
**Sponsor:** Cystic Fibrosis Foundation Therapeutics, Inc.  
**Project Dates and Amount of Award:** 01/01/09-12/31/09; \$108,000

**PI:** Prosser, Lisa  
**Title:** JOINT INITIATIVE FOR VACCINE ECONOMICS III (JIVE III)  
**Sponsor:** CDC-Subcontracts TO Harvard Pilgrim Health Care  
**Project Dates and Amount of Award:** 10/17/08-09/29/09; \$51,217

**PI:** Shellhaas, Renee  
**Co-I:** Barks, John (Pediatrics-Neonatal/Perinatal)  
**Title:** REWARMING AFTER THERAPEUTIC HYPOTHERMIA IN NEONATES  
**Sponsor:** Child Neurology Foundation  
**Project Dates and Amount of Award:** 01/01/09-12/31/10; \$100,000

## Pharmacology

**PI:** Satin, Leslie  
**Title:** METABOLICALLY COUPLED ION CHANNEL INTERACTIONS IN ISLETS  
**Sponsor:** NIH 7 R01 DK 046409 16  
**Project Dates and Amount of Award:** 12/01/08-11/30/10; \$620,782

**PI:** Satin, Leslie  
**Title:** ALTERED EXCITATORY NEUROTRANSMISSION AFTER BRAIN TRAUMA  
**Sponsor:** NIH 7 R01 NS 049519 03  
**Project Dates and Amount of Award:** 07/01/08-12/31/10; \$799,655

## Psychiatry

**PI:** Kim, Scott  
**Co-I:** De Vries, Raymond (Med Ed/Ofc of Ed Resources&Res) / Kim, Hyungjin (Ctr Statistical Consul & Res)  
**Title:** THERAPEUTIC MISCONCEPTION AND THE ETHICS OF SHAM SURGERY CONTROLS IN PD RESEARCH  
**Sponsor:** NIH 1 R01 NS 062770 01 A1  
**Project Dates and Amount of Award:** 03/01/09-02/28/13; \$1,393,176

## Radiology

**PI:** Jiang, John  
**Title:** SPECIMEN ANALYSIS: INFLAMMATORY ARTHRITIS IN RODENTS  
**Sponsor:** Ardea Biosciences  
**Project Dates and Amount of Award:** 02/05/09-04/15/09; \$7,000

## Surgery

**PI:** Eliason, Jonathan  
**Title:** TEMPORARY VASCULAR SHUNTING IN A PORCINE (SUS SCROFA) MODEL OF EXTREMITY VASCULAR INJURY AND ISCHEMIA REPERFUSION: IMPACT OF SHUNT TIMING, VENOUS SHUNTING AND THERAPEUTIC SHUNTING  
**Sponsor:** Defense, Department of-Air Force, Department of the  
**Project Dates and Amount of Award:** 08/29/08-05/29/09; \$83,720

**PI:** Misek, David  
**Title:** ANALYSIS OF GLYCAN STRUCTURAL MODIFICATIONS TO IDENTIFY IMPROVED BIOMARKERS FOR BREAST CANCER DETECTION  
**Sponsor:** US DOD-Army, Department of the  
**Project Dates and Amount of Award:** 01/15/09-04/14/12; \$569,942

**PI:** Sung, Randall  
**Title:** I5NP FOR PROPHYLAXIS OF DELAYED GRAFT FUNCTION IN PATIENTS UNDERGOING DECEASED DONOR KIDNEY TRANSPLANTATION (QUARK.006 CONTROLLED, RANDOMIZED, PROSPECTIVE, DOUBLE-BLIND, MULTICENTER, PHASE VII, DOSE-ESCALATION STUDY OF THE SAFETY, PK, AND CLINICAL ACTIVITY OF)  
**Sponsor:** Quark Biotech USA TO CTI Clinical Trial and Consulting Services  
**Project Dates and Amount of Award:** 01/26/09-12/31/10; \$72,418

## Urology

**PI:** Roberts, William  
**Title:** AUA SUPPLEMENTAL FUNDING: K-AWARD  
**Sponsor:** American Urological Association Foundation  
**Project Dates and Amount of Award:** 01/01/09-12/31/11; \$101,000

# UMMS RESEARCH PUBLICATIONS

## Biological Chemistry

Harding HP, Zhang Y, Scheuner D, Chen JJ, Kaufman RJ, Ron D. Ppp1r15 gene knockout reveals an essential role for translation initiation factor 2 alpha (eIF2alpha) dephosphorylation in mammalian development. *Proc Natl Acad Sci USA*. 2009 Feb 10; 106(6): 1832-7.

Hildebrandt F, Heeringa SF, Rüschemdorf F, Attanasio M, Nürnberg G, Becker C, Seelow D, Huebner N, Chernin G, Vlangos CN, Zhou W, O'Toole JF, Hoskins BE, Wolf MT, Hinkes BG, Chaib H, Ashraf S, Allen SJ, Vega-Warner V, Wise E, Harville HM, Lyons RH, Washburn J, Macdonald J, Nürnberg P, Otto EA. A systematic approach to mapping recessive disease genes in individuals from outbred populations. *PLoS Genet*. 2009 Jan; 5(1): e1000353.

Houglund JL, Lamphear CL, Scott SA, Gibbs RA, Fierke CA. Context-Dependent Substrate Recognition by Protein Farnesyltransferase (dagger). *Biochemistry*. 2009 Feb 6 (Epub ahead of print).

Liu G, Li W, Wang L, Kar A, Guan KL, Rao Y, Wu JY. DSCAM functions as a netrin receptor in commissural axon pathfinding. *Proc Natl Acad Sci USA*. 2009 Feb 5 (Epub ahead of print).

Marinec PS, Chen L, Barr KJ, Mutz MW, Crabtree GR, Gestwicki JE. FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo. *Proc Natl Acad Sci USA*. 2009 Feb 3; 106(5): 1336-41.

Padhani AR, Liu G, Mu-Koh D, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. *Neoplasia*. 2009 Feb; 11(2): 102-25.

Raunser S, Magnani R, Huang Z, Houtz RL, Trievel RC, Penczek PA, Walz T. Rubisco in complex with Rubisco large subunit methyltransferase. *Proc Natl Acad Sci USA*. 2009 Feb 10 (Epub ahead of print).

Ren G, Stephan D, Xu Z, Zheng Y, Tang D, Harrison RS, Kurz M, Jarrott R, Shouldice SR, Hiniker A, Martin JL, Heras B, Bardwell JC. Properties of the thioredoxin-fold superfamily are modulated by a single amino acid residue. *J Biol Chem*. 2009 Jan 30 (Epub ahead of print).

Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely ED, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. *JAMA*. 2009 Feb 4; 301(5): 489-99.

Wang J, Farr GW, Zeiss CJ, Rodriguez-Gil DJ, Wilson JH, Furtak K, Rutkowski DT, Kaufman RJ, Ruse CI, Yates JR 3rd, Perrin S, Feany MB, Horwich AL. Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. *Proc Natl Acad Sci USA*. 2009 Feb 3; 106(5): 1392-7.



Yuan C, Sidhu RS, Kuklev DV, Kado Y, Wada M, Song J, Smith WL. Cyclooxygenase allosterism: Fatty Acid Mediated Cross-talk Between Monomers of Cyclooxygenase homodimers. *J Biol Chem*. 2009 Feb 12 (Epub ahead of print).

## Cell & Developmental Biology

Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM, Everett L, Lenk GM, McKenna-Yasek DM, Weisman LS, Figlewicz D, Brown RH, Meisler MH. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. *Am J Hum Genet*. 2009 Jan; 84(1): 85-8.

Hortsch M, Nagaraj K, Godenschwege TA. The interaction between L1-type proteins and ankyrins – A master switch for L1-type CAM function. *Cell Mol Cell Lett*. 2009; 14: 57-69.

Yamashita YM. Regulation of asymmetric stem cell division: spindle orientation and the centrosome. *Frontiers in Bioscience*. 2009 Jan 1; 14: 3003-3011.

## Family Medicine

Reed BD, Haefner HK, Edwards L. A survey on diagnosis and treatment of vulvodynia among vulvodynia researchers and members of the International Society for the Study of Vulvovaginal Disease. *J Reprod Med*. 2008; 53(12): 921-9.

## Human Genetics

Gruber SB, Mukherjee B. Anticipation in lynch syndrome: still waiting for the answer. *J Clin Oncol*. 2009 Jan 20; 27(3): 326-7.

Hildebrandt F, Heeringa SF, Rüschemdorf F, Attanasio M, Nürnberg G, Becker C, Seelow D, Huebner N, Chernin G, Vlangos CN, Zhou W, O'Toole JF, Hoskins BE, Wolf MT, Hinkes BG, Chaib H, Ashraf S, Allen SJ, Vega-Warner V, Wise E, Harville HM, Lyons RH, Washburn J, Macdonald J, Nürnberg P, Otto EA. A systematic approach to mapping recessive disease genes in individuals from outbred populations. *PLoS Genet*. 2009 Jan; 5(1): e1000353.

Lo AC, Georgopoulos A, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Omar HG, Douglas JA, Merajver SD, Soliman AS. Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients. *Breast*. 2009 Jan 19 (Epub ahead of print).

Lofthus SK, Antonellis A, Matera I, Renaud G, Baxter LL, Reid D, Wolfsberg TG, Chen Y, Wang C; NISC Comparative Sequencing Program, Prasad MK, Bessling SL, McCallion AS, Green ED, Bennett DC, Pavan WJ. *Gpmb* is a melanoblast-expressed, MITF-dependent gene. *Pigment Cell Melanoma Res*. 2009 Feb; 22(1): 99-110.

Mustapha M, Fang Q, Gong TW, Dolan DF, Raphael Y, Camper SA, Duncan RK. Deafness and permanently reduced potassium channel gene expression and function in hypothyroid *Pit1*dw mutants. *J Neurosci*. 2009 Jan 28; 29(4): 1212-23.

Rosenberg NA, Vanliere JM. Replication of genetic associations as pseudoreplication due to shared genealogy. *Genet Epidemiol*. 2009 Feb 3 (Epub ahead of print).

Rowe RG, Li XY, Hu Y, Saunders TL, Virtanen I, de Herreros AG, Becker KF, Ingvarsen S, Engelholm LH, Bommer GT, Fearon ER, Weiss SJ. Mesenchymal cells reactivate *Snail1* expression to drive three-dimensional invasion programs. *J Cell Biol*. 2009 Feb 2 (Epub ahead of print).

Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. *Blood*. 2009 Feb 5; 113(6): 1358-64.

Wojnar M, Brower KJ, Strobbe S, Ilgen M, Matsumoto H, Nowosad I, Sliwerska E, Burmeister M. Association Between Val66Met Brain-Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Post-Treatment Relapse in Alcohol Dependence. *Alcohol Clin Exp Res*. 2009 Jan 17 (Epub ahead of print).

## Internal Medicine

### Infectious Diseases:

Bradley SF. Bennett & Brachman's Hospital Infections, Fifth Edition (book review). *Clin Infect Dis*. 2008; 47: 865.

Chaiyachati K, Cinti SK, Kauffman CA, Riddell J. HIV-Infected patients with anal carcinoma who subsequently developed oral squamous cell carcinoma: Report of 2 cases. *J Intl Ass Phys AIDS Care*. 2008; 7: 306-11.

Cinti SK, Wilkerson W, Holmes JG, Shlafer J, Kim C, Collins CD, Bandy K, Krupansky F, Lozon M, Bradin SA, Wright C, Goldberg J, Wagner D, Rodgers P, Atas J, Cadwallender B. Pandemic Influenza and Acute Care Centers: Taking Care of Sick Patients in a Nonhospital Setting. *Biosecurity Bioterrorism-Biodefense Strategy Practice Science*. 2008; 6(4): 335-348.

Damuth E, Heidelbaugh J, Malani PN, Cinti SK. An Elderly Patient with Fluoroquinolone-Associated Achilles Tendinitis. *Amer J Geriatr Pharmacother*. 2008; 6(5): 264-268.

Durante-Mangoni, Bradley S, Selton-Suty, Tripodi M-F, Pappas P, Sexton D, Fowler V, Bouza E, Murdoch D, Miro JM, Cabell C, Utili R for the International Collaboration on Endocarditis Prospective Cohort Study Group. Infective endocarditis in the elderly: An International Collaboration on Endocarditis Prospective Cohort Study. *Arch Intern Med*. 2008; 168: 2095-2103.

Gandhi T, Flanders SA, Markovitz E, Saint S, Kaul DR. Importance of Urinary Tract Infection to Antibiotic Use Among Hospitalized Patients. *Infect Contr Hosp Epidemiol*. 2009; 30(2): 193-195.

Hadley S, Huckabee C, Pappas PG, Daly J, Rabkin J, Kauffman CA, Merion RM, Karchmer AW. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. *Transpl Infect Dis*. 2009; 11: 40-48.

Kauffman CA, Carver PL. Update on echinocandin antifungals. *Sem Respir Crit Care Med*. 2008; 29: 211-219.

Malani AN, Aronoff DM. Voriconazole-induced phototoxicity. *Clin Med Res*. 2008; 6(2): 83-85.

Meurer WJ, Smith BL, Losman ED, Sherman D, Yaksich JD, Jared JD, Malani PN, Younger JG. Real-Time Identification of Serious Infection in Geriatric Patients Using Clinical Information System Surveillance. *J Amer Geriatr Soc*. 2009; 57(1): 40-45.

Peres E, Khaled Y, Krijanovski OI, Mineishi S, Levine JE, Kaul DR, Riddell J. Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline. *Transpl Infect Dis*. 2009; 11: 57-63.

Psarros G, Kaul DL, Kauffman CA. Disseminated histoplasmosis in a heart transplant recipient: an uncommon diagnosis even in the Midwest. *Infect Dis Clin Pract*. 2008; 16: 49-53.

Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K. Prevention and Treatment of Cancer Related Infections. *Journal of the National Comprehensive Cancer Network*. 2008; 6(2): 122-74.

Tran MP, Caldwell-McMillan M, Khalife WT, and Young VB. Streptococcus intermedius causing infective endocarditis and abscesses: a report of three cases and review of the literature. *BMC Infect Dis*. 2008; 8: 154.

Walk ST, Young VB. Emerging insights into antibiotic-associated diarrhea and Clostridium difficile infection through the lens of microbial ecology. *Review. Interdiscip Perspect Infect Dis*. 2008; 2008: 125081.

## Microbiology and Immunology

Balin SJ, Platt JL, Cascalho M. Noncognate function of B cells in transplantation. *Transpl Int*. 2009 Jan 15 (Epub ahead of print).

Buchholz TJ, Geders TW, Bartley FE 3rd, Reynolds KA, Smith JL, Sherman DH. Structural basis for binding specificity between subclasses of modular polyketide synthase docking domains. *ACS Chem Biol*. 2009 Jan 16; 4(1): 41-52.

Chamberland S, Grüschow S, Sherman DH, Williams RM. Synthesis of Potential Early-Stage Intermediates in the Biosynthesis of FR900482 and Mitomycin C. *Org Lett*. 2009 Jan 22 (Epub ahead of print).

Cooper S, Gonzalez-Hernandez M. Experimental reconsideration of the utility of serum starvation as a method for synchronizing mammalian cells. *Cell Biol Int*. 2009 Jan; 33(1): 71-7.

Edwards RL, Dalebroux ZD, Swanson MS. Legionella pneumophila Couples Fatty Acid Flux to Microbial Differentiation and Virulence. *Mol Microbiol*. 2009 Jan 6 (Epub ahead of print).

Hoppe AD, Seveau S, Swanson JA. Live Cell Fluorescence Microscopy to Study Microbial Pathogenesis. *Cell Microbiol*. 2009 Jan 5 (Epub ahead of print).

Kirschner DE, Linderman JJ. Mathematical and computational approaches can complement experimental studies of host-pathogen interactions. *Cell Microbiol*. 2008 Dec 29 (Epub ahead of print).

Lau HY, Huffnagle GB, Moore TA. Host and microbiota factors that control Klebsiella pneumoniae mucosal colonization in mice. *Microbes Infect*. 2008 Oct; 10(12-13): 1283-90.

Raghavan M, Del Cid N, Rizvi SM, Peters LR. MHC class I assembly: out and about. *Trends Immunol*. 2008 Sep; 29(9): 436-43. Review.

Raman S, Hsu TH, Ashley SL, Spindler KR. Integrin and Heparan Sulfate Usage as Receptors for Mouse Adenovirus Type 1. *J Virol*. 2009 Jan 28 (Epub ahead of print).

Robinson M, Li B, Ge Y, Ko D, Yendluri S, Harding T, Vanroy M, Spindler KR, Jooss K. A novel immune-competent murine tumor model for the evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. *J Virol*. 2009 Feb 4 (Epub ahead of print).

Sofi MH, Li W, Kaplan MH, Chang CH. Elevated IL-6 expression in CD4 T cells via PKC $\theta$  and NF- $\kappa$ B induces Th2 cytokine production. *Mol Immunol*. 2009 Jan 30 (Epub ahead of print).

## Neurology

Lorincz MT, Zawistowski VA. Expanded CAG repeats in the murine Huntington's disease gene increases neuronal differentiation of embryonic and neural stem cells. *Mol Cell Neurosci*. 2009 Jan; 40(1): 1-13.

## Neurosurgery

Poulter GT, Garton HJ, Blakemore LC, Hensinger RN, Graziano GP, Farley FA. Mortality and morbidity associated with correction of severe cervical hyperextension. *Spine*. 2009 Feb 15; 34(4): 378-83.

Sangala JR, Uribe JS, Park P, Martinez C, Vale FL. Nerve root prolapse into a spinal arachnoid cyst-An unusual cause of radiculopathy. *Clin Neurol Neurosurg*. 2009 Jan 29 (Epub ahead of print).

## Obstetrics & Gynecology

Cooper SM, Haefner HK, Abrahams-Gessel S, Margesson LJ. Vulvovaginal lichen planus treatment: a survey of current practices.[see comment]. [Letter] *Archives of Dermatology*. 2008 Nov; 144(11): 1520-1.

Kayampilly PP, Menon KMJ. Follicle-Stimulating Hormone Inhibits Adenosine 5'-Monophosphate-Activated Protein Kinase Activation and Promotes Cell Proliferation of Primary Granulosa Cells in culture through an Akt-Dependent Pathway. *Endocrinology*. 2009 Feb; 150(2): 929-935.

Lewicky-Gaup C, Blaivas J, Clark A, McGuire EJ, Schaer G, Tumbarello J, Tunn R, Delancey JO. "The cough game": are there characteristic urethrovesical movement patterns associated with stress incontinence? *Int Urogynecol J Pelvic Floor Dysfunct*. 2009 Feb; 20(2): 171-5.

Vahratian A. Prevalence of overweight and obesity among women of childbearing age: results from the 2002 national survey of family growth. *Matern Child Health J*. 2009 Mar; 13(2): 268-73.

Xu X, Siefert KA, Jacobson PD, Lori JR, Gueorguieva I, Ransom SB. Malpractice burden, rural location, and discontinuation of obstetric care: A study of obstetric providers in Michigan. *J Rural Health* 2009 Winter; 25(1): 33-42.

## Ophthalmology & Visual Sciences

Kindzelskii AL, Petty HR. Intracellular calcium waves accompany neutrophil polarization, formylmethionylleucylphenylalanine stimulation, and phagocytosis: a high speed microscopy study. *J Immunol* 2009; 182(3): 1770.

Malta JB, Soong HK, Shtein R, Banitt M, Musch DC, Sugar A, Mian SI. Femtosecond laser-assisted keratoplasty: laboratory studies in eye bank eyes. *Curr Eye Res* 2009; 34(1): 18-25.

Parrish RK, 2nd, Feuer WJ, Schiffman JC, Lichter PR, Musch DC. Five-year Follow-up Optic Disc Findings of the Collaborative Initial Glaucoma Treatment Study. *Am J Ophthalmol* 2009 (Epub ahead of print).

Taich A, Johnson MW. A syndrome resembling acute posterior multifocal placoid pigment epitheliopathy in older adults. *Retina* 2009; 29(2): 149-56.

## Orthopaedic Surgery

Kozloff, KM, Quinti L, Patntirapong S, Hauschka P, Tung C, Weissleder R, Mahmood U. Near-infrared optical imaging of cathepsin K-activatable probe reveals osteoclast activity in vitro and in vivo. *Bone*. 2009; 44(2): 190-198.

Peramo A, Marcelo CL, Goldstein SA, Martin DC. Novel organotypic cultures of human skin explants with an implant-tissue biomaterial interface. *Ann Biomed Eng*. 2009; 37(2): 401-409.

## Otolaryngology

Mustapha M, Fang Q, Gong TW, Dolan DF, Raphael Y, Camper SA, Duncan RK. Deafness and permanently reduced potassium channel gene expression and function in hypothyroid Pit1dw mutants. *J Neurosci*. 2009 Jan 28; 29(4): 1212-23.

## Pediatrics & Communicable Diseases

Dowling JJ, Vreede AP, Low SE, Gibbs EM, Kuwada JY, Bonnemann CG, Feldman EL. Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. *PLoS Genet*. 2009 Feb; 5(2): e1000372.

Freed GL, Dunham KM, Abraham L, Research Advisory Committee of the American Board of Pediatrics. Protecting the public: state medical board licensure policies for active and inactive physicians. *Pediatrics*. 2009 Feb; 123(2): 643-52.

Freed GL, Dunham KM, Switalski KE. Clinical inactivity among pediatricians: prevalence and perspectives. *Pediatrics*. 2009 Feb; 123(2): 605-10.

Gregor MA, Wheeler JR, Stanley RM, Mahajan PV, Maio RE, Piette JD; in collaboration with the Great Lakes Emergency Medical Services for Children Research Network. Caregiver adherence to follow up after an emergency department visit for common pediatric illnesses: Impact on future ED uses. *Med Care*. 2009 Jan 21 (Epub ahead of print).

Gurney JG, Krull KR, Kadan-Lottick N, Nicholson HS, Nathan PC, Zebrack B, Tersak JM, Ness KK. Social Outcomes in the Childhood Cancer Survivor Study Cohort. *J Clin Oncol*. 2009 Feb 17 (Epub ahead of print).

Hassan F, Lewis TC, Davis MM, Gebremariam A, Dombkowski K. Hospital utilization and costs among children with influenza. *Am J Prev Med*. 2009 Feb 5 (Epub ahead of print).

Hildebrandt F, Heeringa SF, Ruschendorf F, Attanasio M, Nurnberg G, Becker C, Seelow D, Huebner N, Chernin G, Vlangos CN, Zhou W, O'Toole JF, Hoskins BE, Wolf MT, Hinkes BG, Chaib H, Ashraf S, Allen SJ, Vega-Warner V, Wise E, Harville HM, Lyonds RH, Washburn J, Macdonald J, Nurnberg P, Otto EA. A systematic approach to mapping recessive disease genes in individuals from outbred populations. *PLoS Genet*. 2009 Jan; 5(1): e1000353.

Hoilette LK, Clark SJ, Gebremariam A, Davis MM. Usual source of care and unmet need among vulnerable children 1998-2006. *Pediatrics*. 2009 Feb; 123(2): e214-9.

Jensen DR, Martin DM, Gebarski S, Sahoo T, Brundage EK, Chinault AC, Otto EA, Chaki M, Hildebrandt F, Cheung SW, Lesperance MM. A novel chromosome 19p13.12 deletion in a child with multiple congenital anomalies. *Am J Med Genet A*. 2009 Feb 12 (Epub ahead of print).

Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Iodine-131-Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approach to Neuroblastoma Therapy Phase I Study. *J Clin Oncol*. 2009 Jan 26 (Epub ahead of print).

Owens GE, Gomez-Fifer C, Gelehrter S, Owens ST. Outcomes for patients with unbalanced atrioventricular septal defects. *Pediatr Cardiol*. 2009 Jan 29 (Epub ahead of print).

Shehab N, Mulvahill CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. *Pediatr Crit Care Med*. 2009 Jan 30 (Epub ahead of print).

Stern AM, Markel H. Commentary: Disease etiology and political ideology: revisiting Erwin H Ackerknecht's Classic 1948 Essay, 'Anticontagionism between 1821 and 1867' *Int J Epidemiol*. 2009 Feb; 38(1): 31-3.

Yang J, Schall C, Smith D, Kreuser L, Zamberlan M, King K, Gajarski RJ. HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of Luminex. *J Heart Lung Transplant*. 2009 Feb; 28(2): 123-9.

## Pharmacology

Aman TK, Grieco-Calub TM, Chen C, Rusconi R, Slat EA, Isom LL, Raman IM. Regulation of persistent Na current by interactions among  $\beta$  subunits of voltage-gated Na channels. *J Neuroscience*. 2009 (In press).

Evelyn CR, Ferng T, Rojas RJ, Larsen MJ, Sondek J, Neubig RR. High-Throughput Screening for Small-Molecule Inhibitors of LARG-Stimulated RhoA Nucleotide Binding via a Novel Fluorescence Polarization Assay. *J Biomol Screen*. 2009 Feb 4 (Epub ahead of print).

Foster DJ, Vitvitsky VM, Banerjee R, Heacock AM, Fisher SK. Muscarinic receptor regulation of osmosensitive taurine transport in human SH-SY5Y neuroblastoma cells. *J of Neurochemistry*. 2009; 108: 437-449.

Fujimoto W, Miki T, Ogura T, Zhang M, Sino Y, Satin LS Nakaya H. Niflumic acid-sensitive ion channels play an important role in the induction of glucose-stimulated insulin secretion by cAMP in mice. *Diabetologia*. 2009 (In press).

## Psychiatry

Casher M, Gih D. Complex case: Emergence of borderline personality features in the sixth decade of life. *Personality and Mental Health* 2009 Feb; 3(1): 68-73.

Himelhoch S, McCarthy JF, Ganoczy D, Medoff D, Kilbourne A, Goldberg R, Dixon L, Blow FC. Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. *Psychosomatics*. 2009 Jan-Feb; 50(1): 30-7.

Ilgen MA, Czyz EK, Welsh DE, Zeber JE, Bauer MS, Kilbourne AM. A collaborative therapeutic relationship and risk of suicidal ideation in patients with bipolar disorder. *J Affect Disord*. 2008 Sep 4 (Epub ahead of print).

Irmeter C, Barry KL, Cohen K, Blow FC. Sixteen-year predictors of substance use disorder diagnoses for patients with mental health disorders. *Subst Abus*. 2009; 30(1): 40-6.

Jordan N, Lee TA, Valenstein M, Pirraglia PA, Weiss KB. Effect of Depression Care on Outcomes in COPD Patients With Depression. *Chest*. 2008 Nov 18 (Epub ahead of print).

Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does Adherence to Medications for Type 2 Diabetes Differ Between Individuals With Vs Without Schizophrenia? *Schizophr Bull*. 2008 Aug 20 (Epub ahead of print).

McCarthy JF, Valenstein M, Dixon L, Visnic S, Blow FC, Slade E. Initiation of Assertive Community Treatment Among Veterans With Serious Mental Illness: Client and Program Factors. *Psychiatric Services*. 2009; 60(2): 196-201.

Milner KK, Barry KL, Blow FC, Welsh D. Brief interventions for patients presenting to the psychiatric emergency service (PES) with major mental illnesses and at-risk drinking. *Community Mental Health Journal*. 2009 (In press).

Nesse RM. Evolution: medicine's most basic science. *The Lancet*. 2008; 372: 21-7.

Pasca SP, Nesse RM. Vomiting is not an adaption for glaucoma (and Darwinian medicine is difficult). *Medical Hypotheses*. 2008; 71(3): 472-3.

Pirraglia PA, Biswas K, Kilbourne AM, Fenn H, Bauer MS. A prospective study of the impact of comorbid medical disease on bipolar disorder outcomes. *J Affect Disord*. 2008 Oct 17 (Epub ahead of print).

Schutte K, Yano EM, Kilbourne AM, Wickrama B, Kirchner JE, Humphreys K. Organizational contexts of primary care approaches for managing problem drinking. *J Subst Abuse Treat*. 2008 Nov 11 (Epub ahead of print).

Wojnar M, Brower KJ, Strobbe S, Ilgen M, Matsumoto H, Nowosad I, Sliwerska E, Burmeister M. Association Between Val66Met Brain-Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Post-Treatment Relapse in Alcohol Dependence. *Alcohol Clin Exp Res*. 2009 Jan 17 (Epub ahead of print).

Wojnar M, Ilgen MA, Czyn E, Strobbe S, Klimkiewicz A, Jakubczyk A, Glass J, Brower KJ. Impulsive and non-impulsive suicide attempts in patients treated for alcohol dependence. *J Affect Disord*. 2008 Oct 2 (Epub ahead of print).

Wojnar M, Ilgen MA, Wojnar J, McCammon RJ, Valenstein M, Brower KJ. Sleep problems and suicidality in the National Comorbidity Survey Replication. *J Psychiatr Res*. 2009 Feb; 43(5): 526-531.

Young EA, Becker JB. Perspective: sex matters: gonadal steroids and the brain. *Neuropsychopharmacology*. 2009 Feb; 34(3): 537-8.

Zeber JE, Copeland LA, McCarthy JF, Bauer MS, Kilbourne AM. Perceived Access to General Medical and Psychiatric Care Among Veterans With Bipolar Disorder. *Am J Public Health*. 2009 Jan 15 (Epub ahead of print).

Zivin K, Eisenberg D, Gollust SE, Golberstein E. Persistence of mental health problems and needs in a college student population. *J Affect Disord*. 2009 Jan 27 (Epub ahead of print).

## **Surgery**

### **General Surgery:**

Dehaan AM, Wolters NM, Keller ET, Ignatoski KM. EGFR Ligand Switch in Late Stage Prostate Cancer Contributes to Changes in Cell Signaling and Bone Remodeling. *Prostate*. 2009 Jan 13 (Epub ahead of print).

Maillart LM, Ivy JS, Ransom S, Diehl K. Assessing Dynamic Breast Cancer Screening Policies. *Operation Research* 2008 Nov-Dec; 56(6): 1411-1427.

### **Pediatric Surgery:**

Ehrlich PF, Maio R, Drongowski R, Wagaman M, Cunningham R, Walton M. Alcohol Interventions for Trauma Patients are not Just for Adults. Justification for Brief Interventions for the Injured Adolescent at a Pediatric Trauma Center. *Journal of Trauma*. 2009 (Accepted).

Ehrlich PF, Wee C, Drongowski R, Rana AR. The Canadian C-spine Rule and the National Emergency X-Radiography Utilization Low Risk Criteria for C-spine Radiography in Young Trauma Patients. *Journal of Pediatric Surgery*. 2009 (Accepted).

Pastor AC, Osman F, Teitelbaum DH, Caty MG, Langer JC. Development of a standardized definition for Hirschsprung's-associated enterocolitis: a Delphi analysis. *J Pediatr Surg*. 2009; 44(1): 251-6.

Rana AR, Drongowski R, Breckner G, Ehrlich PF. Traumatic Cervical Spine Imaging: Characteristics of Missed Images. *MSc. J Pediatr Surg*. 2009 Jan; 44(1): 151-5; discussion 155.

Serber J, Stranzinger E, Geiger JD, Teitelbaum DH. Association of gastroschisis and choledochal cyst. *J Pediatr Surg*. 2009 (In press).

Tazuke Y, Teitelbaum DH. Alteration of canalicular transporters in a mouse model of total parenteral nutrition. *J Pediatr Surg* 2009; 44(2): 193-202.

### **Thoracic Surgery:**

Seder CW, Hartojo W, Lin L, Silvers A, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma. *J Thoracic Oncology*. 2009 (In press).

Seder CW, Hartojo W, Lin L, Silvers A, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. Upregulated INHBA Expression May Promote Cell Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma. *Neoplasia*. 2009 (In press).

### **Vascular Surgery:**

Eliason JL, Wakefield TW. Metabolic consequences of acute limb ischemia and their clinical implications. *Semin Vasc Surg*. 2009 1-5.

Ramacciotti E, Hawley AE, Farris DM, Ballard NE, Wroblewski SK, Myers DD, Henke PK, Wakefield TW. Leukocyte and platelet derived MPs correlates to thrombus weight and tissue factor activity in an experimental model of venous thrombosis in mice. *Thromb and Haemost* 2009 (In press).

Wakefield TW, McLafferty RB, Lohr JM, Caprini JA, Gillespie DL, Passman MA. Call to action to prevent venous thromboembolism. *J Vasc Surg*. 2009 (In press).

## **Unit for Laboratory Animal Medicine**

Duran-Struuck R, Dysko RC. Principles of bone marrow transplantation (BMT): providing optimal veterinary and husbandry care to irradiated mice in BMT studies. *J Am Assoc Lab Anim Sci* 2009; 48(1): 11-22.

## **Urology**

Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. *Clin Cancer Res*. 2009 Feb 1; 15(3): 788-96.

Gilbert SM, Hollenbeck BK. Limitations of lymph node counts as a measure of therapy. *J Natl Compr Canc Netw*. 2009 Jan; 7(1): 58-61.

Lange EM, Beebe-Dimmer JL, Ray AM, Zuhlke KA, Ellis J, Wang Y, Walters S, Cooney KA. Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. *Prostate*. 2009 Mar 1; 69(4): 385-91.

Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK. A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone. *Cancer Res*. 2009 Jan 27 (Epub ahead of print).

Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG; the Upper Tract Urothelial Carcinoma Collaboration. The Upper Tract Urothelial Carcinoma Collaboration members: Charles C. Guo, University of Texas M.D. Anderson Cancer Center, USA; Wareef Kabbani, Stephen Lucas, Arthur I. Sagalowsky, The University of Texas Southwestern Medical Center, USA; Cord Langner, University of Graz, Austria; Karim Bensalah, Jean Jacques Patard, CHU Pontchaillou, Rennes, France; Shuji Mikami, Takeo Kosaka, Masaru Isida, Keio University School of Medicine, Japan; Mesut Remzi, Andrea Haitel, Matthias Waldert, University of Vienna, Austria; Pierre I. Karakiewicz, Nazareno Suardi, University of Montreal; Marco Roscigno, Roberto Bertini, Francesco Montorsi, Vita Salute University, Italy; Christian Bolenz, Philipp Stroebel, Maurice Stephan Michel, Universitätsklinikum Mannheim; Casey K. Ng, Douglas S. Scherr, Yingbei Chen, Cornell University, USA; Mario A. Fernández, Clínica Alemana de Santiago, Chile; Jeffrey Wheat, J. Stuart Wolf, Jr., University of Michigan, USA; Theresa M. Koppie, Christopher P. Evans, Eric C. Nelson, University of California Davis Medical Center, USA; Wassim Kassouf, McGill University, Canada. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer*. 2009 Jan 20 (Epub ahead of print).

Mizutani K, Sud S, Pienta KJ. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. *J Cell Biochem*. 2009 Jan 23 (Epub ahead of print).

Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. *J Natl Compr Canc Netw*. 2009 Jan; 7(1): 8-39.

Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM. Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial. *J Natl Cancer Inst*. 2009 Feb 10 (Epub ahead of print).

Scher HI, Xia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. *Lancet Oncol*. 2009 Feb 10 (Epub ahead of print).

Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature*. 2009 Feb 12; 457(7231): 910-4.

Strope SA, Ye Z, Hollingsworth JM, Faerber G, Wolf JS Jr, Wei JT, Hollenbeck BK. Weekend Admission and Treatment of Patients With Renal Colic: A Case of Avoidable Variation? *Urology*. 2009 Feb 2 (Epub ahead of print).